



Outsmarting Cancer, Impacting Lives.

The development of cancer therapies is a high-risk, expensive and time-consuming endeavor, often resulting in new therapies only benefiting a subset of the intended patient population. We aim to change that by revolutionizing preclinical development.


Our Mission

Our 35+ public and private partners, with a homebase in the Netherlands, are united and driven by our mission to collaboratively optimize and accelerate the development of new cancer therapies for the benefit of patients of all ages.

Our Approach

To accelerate the development of safe, personalized and effective therapies, Oncode Accelerator places the patient at the center of preclinical development. We do this by utilizing the power of three innovation Platforms: well-defined Patient Cohorts, patient-derived Organoids, and Artificial Intelligence.

We integrate expertise from our innovation Platforms into drug development pipelines to accelerate the development of four key types of therapies that benefit society: Small Molecules, Biologics, Cell & Gene Therapy, and Therapeutic Vaccines. These four types of therapies make up our Workstreams.



Join Oncode Accelerator

We invite international researchers from across academia and industry to work with us for preclinical development of promising targets by applying for a Demonstrator Project: a selected preclinical discovery or development project for an oncology asset. We offer:

Development Support

Approved projects receive up to 1.5M€ co-funding and project management support to maximize chances of success.

Access to Innovations

Our unique research infrastructure includes advanced technologies, expertise and facilities that support improved and accelerated preclinical development.

Network of Experts

Demonstrator Project partners join a vibrant and impactful ecosystem of world-renowned scientific experts.

Reach out now to get started: demonstrators@oncodeaccelerator.nl

Or find more information on our website: oncodeaccelerator.nl



The Oncode Accelerator Project receives funding from the Dutch National Growth Fund (NGF). It is a collaboration between 6 coordinating partners: Leiden University, Leiden University Medical Center, the Netherlands Cancer Institute, Princess Máxima Center, UMC Utrecht, and the Oncode Accelerator Foundation, who lead individual consortia within the Oncode Accelerator Project.